Best of BS Opinion: UK Covid-19 vaccine, better corporate results and more

Business Standard brings you top Opinion pieces of the day

Best of BS Opinion: UK Covid-19 vaccine, better corporate results and more
UK plans to provide free vaccinations for about 20 million people, with priority going to the elderly
Rajesh Kumar
2 min read Last Updated : Dec 03 2020 | 6:15 AM IST
The United Kingdom became the first country in the world to approve a vaccine for Covid-19 and plans to start vaccinating its population from next week. In this context, our editorial here notes that the UK government’s plan for vaccinating its reasonably multicultural population, though significantly smaller than India’s, could offer some pointers for New Delhi’s vaccine rollout plan in conjunction with the states.

Other opinion pieces for the day talk about corporate earnings and macroeconomic policy.

The corporate results are patchy but encouraging. Tax payout, for instance, has risen 31.2 per cent for the entire sample, shoring up government finances and indicating the reported profits are authentic. Apart from good agri-performance, there was surely some fulfilment of deferred demand after lockdown in Q1. A consumption pickup will be required to sustain this improvement, notes our lead editorial. Read it here

Export capabilities need to be developed and built on scale, adapting policies in other emerging economies such as Bangladesh and Vietnam, writes Shyam Ponappa. Read it here

Quote 
 
“The government has today accepted the recommendation from the independent Medicines and Healthcare products Regulatory Agency (MHRA) to approve Pfizer/BioNTech’s Covid-19 vaccine for use.”  
 
UK Government statement

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :BS OpinionCoronavirus VaccineUK govtIndian companiesIndian Economycorporate earningsIndian export

Next Story